智翔金泰：赛立奇单抗注射液纳入2025年国家医保目录

Core Viewpoint - The announcement by Zhixiang Jintai (688443.SH) regarding the inclusion of its self-developed drug, Saliqi monoclonal antibody injection (Jinlixi), in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List is a significant development that is expected to positively impact the company's long-term operational performance [1] Group 1: Drug Development and Market Impact - The drug is classified as a Class I biological product and is intended for adult patients with moderate to severe plaque psoriasis and adult patients with ankylosing spondylitis who have inadequate response to conventional treatments [1] - The new drug list will officially take effect on January 1, 2026, which is anticipated to facilitate market promotion and future sales of the drug [1] Group 2: Financial Implications - Inclusion in the medical insurance directory is expected to have a positive effect on the company's long-term operating performance [1] - However, the actual sales will be influenced by various factors, including the medical insurance payment standards and reimbursement details as per the information published by the National Healthcare Security Administration, indicating some level of uncertainty [1]